Rohto Pharmaceutical Co.,Ltd.
Notice Regarding the Revision of Earnings Forecast
Consolidated earnings forecast for the fiscal year ending March 2027 raised. Net sales increased by 2,800 million yen from the previous forecast, operating income by 2,700 million yen, ordinary income by 1,300 million yen, net income attributable to owners of the parent by 700 million yen, and basic earnings per share increased by about 3.10 yen. Improvements attributed to revised exchange rate assumptions and strength in the first quarter.
Key Figures
- 372,300 billion yen: Net sales (YoY +2,800 billion yen)
- 45,000 billion yen: Operating income (YoY +1,200 billion yen)
- 47,400 billion yen: Ordinary income (YoY +1,300 billion yen)
AI要約
Revision of earnings outlook
Rohto Pharmaceutical Co., Ltd. revised its consolidated earnings forecast announced on May 13, 2026. The new full-year forecast shows net sales of 372,300 billion yen, operating income of 45,000 billion yen, ordinary income of 47,400 billion yen, net income attributable to owners of the parent of 35,200 billion yen, and basic earnings per share of 155.78 yen. The revisions reflect updated foreign exchange assumptions of 1 USD = 158 yen and 1 CNY = 23 yen, and solid performance in the first-quarter cumulative results across Asia, Japan, and Europe segments. The outlook is expected to exceed the previous forecast and show improvement versus the prior year and past results.
Outlook and risks
The revision is largely attributed to changes in exchange rate assumptions and segment momentum; future actual results may vary depending on exchange rate movements and market conditions. The final results will depend on future economic fluctuations and exchange rate trends.
Rohto Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
